Please use this identifier to cite or link to this item: http://hdl.handle.net/1822/38393

TitleTriple negative breast cancer: nanosolutions for a big challenge
Author(s)Mendes, T.
Kluskens, Leon
Rodrigues, L. R.
Keywordsnanotechnology
drug delivery
diagnostics
cancer therapy
triple negative breast cancer (TNBC)
Issue dateNov-2015
PublisherWiley-VCH Verlag
JournalAdvanced Science
CitationMendes, T.; Kluskens, Leon; Rodrigues, L. R., Triple negative breast cancer: nanosolutions for a big challenge. Advanced Science, 2(11), 1-14, 2015
Abstract(s)Triple negative breast cancer (TNBC) is a particular immunopathological subtype of breast cancer that lacks expression of estrogen and progesterone receptors (ER/PR) and amplification of the human epidermal growth factor receptor 2 (HER2) gene. Characterized by aggressive and metastatic phenotypes and high rates of relapse, TNBC is the only breast cancer subgroup still lacking effective therapeutic options, thus presenting the worst prognosis. The development of targeted therapies, as well as early diagnosis methods, is vital to ensure an adequate and timely therapeutic intervention in patients with TNBC. This review intends to discuss potentially emerging approaches for the diagnosis and treatment of TNBC patients, with a special focus on nano-based solutions that actively target these particular tumors.
TypeArticle
URIhttp://hdl.handle.net/1822/38393
DOI10.1002/advs.201500053
ISSN2198-3844
e-ISSN2198-3844
Publisher versionhttp://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2198-3844
Peer-Reviewedyes
AccessOpen access
Appears in Collections:CEB - Publicações em Revistas/Séries Internacionais / Publications in International Journals/Series

Files in This Item:
File Description SizeFormat 
document_22162_1.pdf610,92 kBAdobe PDFView/Open

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID